Academic Journal
JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy
| العنوان: | JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy |
|---|---|
| المؤلفون: | Vannucchi A. M., Mortara A., D'alessio A., Morelli M., Tedeschi A., Festuccia M. B., Monforte A. D., Capochiani E., Selleri C., Simonetti F., Saracino A., Rapezzi D., Badagliacca M. R., Falasca K., Molteni A., Palazzolo R., Schettino G., Bocchia M., Turrini M., Ascierto P. A., Zuurman M., Paley C., Coco P., Saglio G. |
| المساهمون: | Vannucchi, A. M., Mortara, A., D'Alessio, A., Morelli, M., Tedeschi, A., Festuccia, M. B., Monforte, A. D., Capochiani, E., Selleri, C., Simonetti, F., Saracino, A., Rapezzi, D., Badagliacca, M. R., Falasca, K., Molteni, A., Palazzolo, R., Schettino, G., Bocchia, M., Turrini, M., Ascierto, P. A., Zuurman, M., Paley, C., Coco, P., Saglio, G. |
| سنة النشر: | 2021 |
| المجموعة: | ARUd'A - Archivio Istituzionale della ricerca dell'università Chieti-Pescara (IRIS) |
| مصطلحات موضوعية: | COVID‐19, Hyperactive inflammatory response, Pneumonia, Ruxolitinib, SARS‐CoV‐2 |
| الوصف: | Jak inhibitors are potent anti‐inflammatory drugs that have the potential to dampen the hyperactive inflammatory response associated with severe COVID‐19. We reviewed the clinical outcomes of 218 patients with COVID‐19 hospitalized for severe pneumonia and treated with ruxolitinib through a compassionate use program. Data on the duration of treatment; outcomes at 4, 7, 14, and 28 days; oxygen support requirements; clinical status; and laboratory parameters were retrospectively collected. Overall, according to the physician evaluation, 66.5% of patients showed improvement at follow‐up; of these, 83.5% showed improvement by day 7. Oxygen support status also showed improvement, and by day 7, 21.6% of patients were on ambient air, compared with 1.4% at baseline, which increased to 48.2% by day 28. Significant decreases in C‐reactive protein and increases in the lymphocyte total count were already observed by day 4, which seemed to correlate with a positive outcome. At the end of the observation period, 87.2% of patients were alive. No unexpected safety findings were observed, and grade 3/4 adverse events were reported in 6.9% of patients. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/34442045; info:eu-repo/semantics/altIdentifier/wos/WOS:000690551100001; volume:10; issue:16; firstpage:3752; journal:JOURNAL OF CLINICAL MEDICINE; http://hdl.handle.net/11564/769271; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85113804747; https://www.mdpi.com/2077-0383/10/16/3752 |
| DOI: | 10.3390/jcm10163752 |
| الاتاحة: | http://hdl.handle.net/11564/769271 https://doi.org/10.3390/jcm10163752 https://www.mdpi.com/2077-0383/10/16/3752 |
| Rights: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.8FCB9CF2 |
| قاعدة البيانات: | BASE |
| DOI: | 10.3390/jcm10163752 |
|---|